Stem Cells
Therapies
Stem Cells Therapies
The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China).
FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials.
Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders.
Check the full list of patients who received stem cell therapy derived from FamiCord labs.
List last update: 06.2026
List of patients who received stem cells from FamiCord Group laboratories
| Lp. | Source | Source type | Diagnosis | Medical field | Year of application | Therapy | Country | Age of recipient |
|---|---|---|---|---|---|---|---|---|
| 101 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia (Relapse) | Hematology | 2026 | Standard Therapy | Germany | 66 |
| 102 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Germany | 70 |
| 103 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | France | 42 |
| 104 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Netherlands | 57 |
| 105 | Bone Marrow Family | Allogeneic | Polycythaemia Vera | Hematology | 2026 | Standard Therapy | Germany | 61 |
| 106 | Bone Marrow Family | Allogeneic | CMML – Beginning Relapse | Hematology | 2026 | Standard Therapy | Netherlands | 63 |
| 107 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Australia | 64 |
| 108 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Poland | 76 |
| 109 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Switzerland | 66 |
| 110 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Finland | 40 |
| 111 | Bone Marrow Family | Allogeneic | T-Cell Prolymphocytic Leukemia | Hematology | 2026 | Standard Therapy | Norway | 64 |
| 112 | Bone Marrow Family | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | Spain | 47 |
| 113 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Poland | 66 |
| 114 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Czechia | 68 |
| 115 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Poland | 26 |
| 116 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | hematology | 2026 | Standard Therapy | Germany | 67 |
| 117 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | hematology | 2026 | Standard Therapy | Germany | 51 |
| 118 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | France | 67 |
| 119 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | USA | 30 |
| 120 | Bone Marrow Family | Allogeneic | Acute Lymphoblastic Leukemia | hematology | 2026 | Standard Therapy | Hungary | 10 |
| 121 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | Germany | 63 |
| 122 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia / MDR Relapse | hematology | 2026 | Standard Therapy | Ukraine | 39 |
| 123 | Bone Marrow Family | Allogeneic | Chronic Myelomonocytic Leukemia | hematology | 2026 | Standard Therapy | USA | 70 |
| 124 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | Poland | 72 |
| 125 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Germany | 3 |
| 126 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Hungary | 62 |
| 127 | Bone Marrow | Allogeneic | Fanconi Anemia | Hematology | 2026 | Standard Therapy | Austria | 7 |
| 128 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Belgium | 12 |
| 129 | Bone Marrow | Allogeneic | Combined Immunodeficiency | Hematology | 2026 | Standard Therapy | Belgia | 3 |
| 130 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Italy | 60 |
| 131 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | Italy | 7 |
| 132 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | Italy | 4 |
| 133 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Germany | 8 |
| 134 | Bone Marrow | Allogeneic | Other Immune System | Hematology | 2026 | Standard Therapy | USA | 5 |
| 135 | Bone Marrow | Allogeneic | Adrenoleukodystrophy (X-ALD) | Hematology | 2026 | Standard Therapy | Czechia | 5 |
| 136 | Bone Marrow | Allogeneic | Wiskott-Aldrich Syndrome | Hematology | 2026 | Standard Therapy | Germany | 19 |
| 137 | Bone Marrow | Allogeneic | Wiskott-Aldrich Syndrome | Hematology | 2026 | Standard Therapy | USA | 11 |
| 138 | Bone Marrow | Allogeneic | Serum Amyloid A (SAA) | Hematology | 2026 | Standard Therapy | Austria | 16 |
| 139 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2026 | Standard Therapy | France | 32 |
| 140 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2026 | Standard Therapy | Germany | 16 |
| 141 | Bone Marrow | Allogeneic | Other Malignancy | Hematology | 2026 | Standard Therapy | France | 5 |
| 142 | Bone Marrow | Allogeneic | Mixed type Leukemia | Hematology | 2026 | Standard Therapy | Poland | 1 |
| 143 | Bone Marrow | Allogeneic | OIID, Chronic Granulomatous Disease CGD | Hematology | 2026 | Standard Therapy | Germany | 2 |
| 144 | Bone Marrow | Allogeneic | GATA2 deficiency | Hematology | 2026 | Standard Therapy | Belgium | 12 |
| 145 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Italy | 48 |
| 146 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Poland | 47 |
| 147 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | United Kingdom | 80 |
| 148 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2026 | Standard Therapy | United Kingdom | 15 |
| 149 | Bone Marrow | Allogeneic | Severe Aplastic Anemia / AA Amyloidosis | Hematology | 2026 | Standard Therapy | United Kingdom | 24 |
| 150 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Turkey | 8 |
| 151 | Bone Marrow | Allogeneic | SCID Severe Combined Immunodeficiency | Hematology | 2026 | Standard Therapy | Poland | 1 |
| 152 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2026 | Standard Therapy | Germany | 58 |
| 153 | Bone Marrow | Allogeneic | Pure Red Cell Aplasia | Hematology | 2026 | Standard Therapy | USA | 29 |
| 154 | Bone Marrow | Allogeneic | Combined Immunodeficiency | Hematology | 2026 | Standard Therapy | USA | 19 |
| 155 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2026 | Standard Therapy | France | 21 |
| 156 | Bone Marrow | Allogeneic | B-thalassemia | Hematology | 2026 | Standard Therapy | Netherlands | 15 |
| 157 | Bone Marrow | Allogeneic | Very Severe Aplastic Anemia | Hematology | 2026 | Standard Therapy | Slovakia | 31 |
| 158 | Bone Marrow | Allogeneic | Hemophagocytic Lymphohistiocytosis | Hematology | 2026 | Standard Therapy | Austria | 3 |
| 159 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Poland | 12 |
| 160 | Bone Marrow | Allogeneic | Diamond Blackfan Anemia | Hematology | 2026 | Standard Therapy | Slovakia | 9 |
| 161 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Brazil | 62 |
| 162 | Bone Marrow | Allogeneic | Griscelli syndrome type 2 | Hematology | 2026 | Standard Therapy | Canada | 39 |
| 163 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | France | 47 |
| 164 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | USA | 21 |
| 165 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | Hungary | 10 |
| 166 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Poland | 70 |
| 167 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | USA | 6 |
| 168 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia CR2 | Hematology | 2026 | Standard Therapy | Spain | 9 |
| 169 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | France | 7 |
| 170 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Hungary | 23 |
| 171 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2026 | Standard Therapy | USA | 8 |
| 172 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2026 | Standard Therapy | USA | 20 |
| 173 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Poland | 1 |
| 174 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2026 | Standard Therapy | USA | 13 |
| 175 | Bone Marrow | Allogeneic | Severe Combined Immunodeficiency | Hematology | 2026 | Standard Therapy | USA | 2 |
| 176 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2026 | Standard Therapy | Italy | 3 |
| 177 | Bone Marrow | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2026 | Standard Therapy | USA | 26 |
| 178 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Hungary | 9 |
| 179 | Bone Marrow | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2026 | Standard Therapy | Spain | 61 |
| 180 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Germany | 2 |
| 181 | Bone Marrow | Allogeneic | Other Leukaemia | Hematology | 2026 | Standard Therapy | France | 1 |
| 182 | Bone Marrow | Allogeneic | – | Hematology | 2026 | Standard Therapy | Germany | 16 |
| 183 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2026 | Standard Therapy | Belarus | 2 |
| 184 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | United Kingdom | 11 |
| 185 | Bone Marrow | Allogeneic | Sickle Cell Disease | hematology | 2026 | Standard Therapy | Netherlands | 18 |
| 186 | Bone Marrow | Allogeneic | Non-Hodgkin Lymphoma | hematology | 2026 | Standard Therapy | Germany | 6 |
| 187 | Bone Marrow | Allogeneic | Fanconi Anemia | hematology | 2026 | Standard Therapy | USA | 7 |
| 188 | Bone Marrow | Allogeneic | Other Combined Immunodeficiency | hematology | 2026 | Standard Therapy | USA | 8 |
| 189 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | Spain | 14 |
| 190 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | hematology | 2026 | Standard Therapy | Poland | 3 |
| 191 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | hematology | 2026 | Standard Therapy | Italy | 1 |
| 192 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | hematology | 2026 | Standard Therapy | USA | 76 |
| 193 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | Germany | 38 |
| 194 | Bone Marrow | Allogeneic | Sickle cell disease | hematology | 2026 | Standard Therapy | Netherlands | 17 |
| 195 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2026 | Standard Therapy | Germany | 61 |
| 196 | Apheresis | Autologous | Plasmablastic Lymphoma | Hematology | 2026 | Standard Therapy | Germany | 69 |
| 197 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2026 | Standard Therapy | Germany | 60 |
| 198 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2026 | Standard Therapy | Portugal | 54 |
| 199 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2026 | Standard Therapy | Portugal | 67 |
| 200 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | France | 68 |